Navigation Links
BD Biosciences to Distribute FCS Express
Date:1/26/2009

LOS ANGELES, Jan. 26 /PRNewswire/ -- De Novo Software(TM), a leading provider of flow cytometry data analysis solutions, announced today an agreement with BD Biosciences to sell De Novo Software's flagship product -- FCS Express(TM) -- to customers in clinical, research and pharmaceutical markets worldwide. BD Biosciences, a segment of BD (Becton, Dickinson and Company) is a pioneer and leader in flow cytometry systems and reagents.

"We look forward to providing BD customers with enhanced flow cytometry data analysis capabilities," said De Novo Software President David Novo. "BD Biosciences and De Novo Software will work together to ensure our customers have a positive support experience and build on the existing BD FACSDiva(TM) software integration capabilities present in FCS Express."

Used today by many leading clinical and research laboratories, FCS Express provides comprehensive analysis capabilities, including advanced and easy-to-use report creation tools, 21 CFR Part 11 data security support, quality control alerts and histogram overlays.

"BD Biosciences is committed to offering comprehensive, innovative solutions to support the work of researchers and clinicians in their efforts to understand disease and improve care," said Andy Last, Vice President, Global Marketing and Strategic Planning, BD Biosciences. "FCS Express is the industry's only third-party analysis software for flow cytometry that is registered with the FDA for IVD use. It meets clinical customer requirements and adds new capabilities that complement BD FACSDiva(TM) software."

Customers will be able to purchase FCS Express through the BD Biosciences sales force, website and catalog.

For more information, please visit www.denovosoftware.com or www.bdbiosciences.com

    Contact Information:
    David Novo                        Jim Harper
    President                         Software Product Manager
    De Novo Software                  BD Biosciences
    info@denovosoftware.com           jim_harper@bd.com
    213.814.1240                      408.954.2561

About De Novo Software

De Novo Software provides integrated solutions for the life sciences, primarily in the field of flow cytometry data analysis. Its primary product, FCS Express, is used by over one thousand laboratories worldwide for research purposes, and dozens of clinical laboratories for high throughput clinical analysis. As the only third-party flow analysis software registered with the FDA for in-vitro diagnostic use, FCS Express is the analysis tool of choice for the clinical laboratory. In addition, De Novo Software has extensive experience creating custom data analysis solutions and integrating with large scale LIS and HIS systems. For more information, please visit www.denovosoftware.com.


'/>"/>
SOURCE De Novo Software
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
2. Cell Biosciences Introduces Kits for Oncoprotein Analysis
3. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
4. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
5. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
6. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
7. Cell Biosciences Delivers Next Generation System to Stanford University
8. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
9. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
10. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced that it has joined the Human Vaccines Project, a public-private partnership ... and cancer. , The Human Vaccines Project brings together leading pharmaceutical ...
(Date:2/10/2016)... -- Allergan plc (NYSE: AGN ) a leading global ... Allergan,s CEO and President, will be featured as the ... RBC Capital Markets Healthcare Conference on Tuesday, February 23, ... Palace Hotel in New York, NY ... be accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
Breaking Biology News(10 mins):